{"id":390518,"date":"2018-12-20T00:00:00","date_gmt":"2018-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2018-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-03-31T10:47:34","modified_gmt":"2026-03-31T10:47:34","slug":"dlsfon0017-2018-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2018-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p><strong>Market Outlook:<\/strong><\/p>\n<p>Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety of multimodal approaches; advanced (metastatic) disease is treated with palliative intent. Few pharmacological interventions are approved for advanced HCC, with Bayer HealthCare\/Amgen\/Onyx\u2019s Nexavar as the long-standing, only first-line treatment option available. In the recurrent setting, Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s PD-1 inhibitor, Opdivo, has captured significant market shares since its approval in 2017. The late-phase development pipeline is predominantly focused on the advanced HCC population segment and encompasses a diverse range of mechanisms of action. Because the HCC market is largely untapped, the developer of an efficacious therapy could reap high commercial rewards.<\/p>\n<p><strong>Questions Answered: <\/strong><\/p>\n<p>How large is the treatable HCC population and how will drug-treatment rates change over time?<\/p>\n<p>How is HCC currently treated, and what are interviewed experts\u2019 insights on current treatment options?<\/p>\n<p>What clinical needs remain unfulfilled? Who are the key players in the late-phase development pipeline for HCC?<\/p>\n<p>Which agents or drug classes are most promising? What therapies of note are progressing in earlier phases?<\/p>\n<p>Which emerging therapies do we forecast to enter each of the hepatocellular carcinoma market segments?<\/p>\n<p>What uptake and sales are these therapies anticipated to secure?<\/p>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Markets covered: <\/strong><\/p>\n<ul>\n<li>United States<\/li>\n<li>France<\/li>\n<li>Germany<\/li>\n<li>Italy<\/li>\n<li>Spain<\/li>\n<li>United Kingdom<\/li>\n<li>Japan.<\/li>\n<\/ul>\n<p><strong>Primary research:<\/strong> Twenty country-specific interviews with thought leaders (medical oncologists and hepatologists).<\/p>\n<p><strong>Key companies: <\/strong><\/p>\n<ul>\n<li>Bayer HealthCare<\/li>\n<li>Bristol-Myers Squibb\/Ono Pharmaceuticals<\/li>\n<li>Merck &#038; Co.\/MSD<\/li>\n<li>Eisai<\/li>\n<li>Exelixis\/Ipsen.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390518","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390518\/revisions"}],"predecessor-version":[{"id":576667,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390518\/revisions\/576667"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}